Nanoparticle Delivery Systems in the Treatment of Diabetes Complications

Souto, Eliana B.; Souto, Selma B.; Campos, J.; Severino, Patrícia; Pashirova, Tatiana N.; Zakharova, L. Ya.; Silva, Amélia M.; Durazzo, Alessandra; Lucarini, Massimo; Izzo, Angelo A.; Santini, Antonello

doi:10.3390/molecules24234209

Cited by 124 publications

(58 citation statements)

References 206 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The epidemic metabolic disorder, diabetes mellitus (DM) is characterized by high blood glucose where the patient cannot produce adequate insulin, or body cells do not respond to glucose produced by β-cells in the pancreas. Many people have diabetes all over the world [1][2][3], and the number is increasing at an alarming rate. According to the World Health Organization, diabetes causes 1.5 million deaths each year worldwide, being one of the most recurrent cause of mortality in developed countries [2].…”

Section: Introductionmentioning

confidence: 99%

“…Many people have diabetes all over the world [1][2][3], and the number is increasing at an alarming rate. According to the World Health Organization, diabetes causes 1.5 million deaths each year worldwide, being one of the most recurrent cause of mortality in developed countries [2]. The high blood sugar of diabetic patients leads to the typical symptoms of polyuria, polydipsia and polyphagia [4].…”

Section: Introductionmentioning

confidence: 99%

“…Simpler and painless routes for insulin administration are still in demand to manage diabetes as conventional drug delivery systems still have numerous drawbacks, including improper and/or ineffective dosage, low potency, limited specificity for the target, which may result in adverse side effects in other organs/tissues. The use of natural products could be the potential to encounter the limitations of DM treatment [2,14,15]. To overcome the pharmacokinetic limitations of drugs, the novel drug delivery system has considered as an attractive option to deliver the drugs for treating several diseases and disorders [2,[16][17][18].…”

Section: Introductionmentioning

confidence: 99%

“…The use of natural products could be the potential to encounter the limitations of DM treatment [2,14,15]. To overcome the pharmacokinetic limitations of drugs, the novel drug delivery system has considered as an attractive option to deliver the drugs for treating several diseases and disorders [2,[16][17][18]. The loading of insulin, and other sugar-lowering drugs and nutraceuticals, into nanoparticles, has been proposed as a more convenient, non-invasive and safer approach through alternative administration routes [2].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

et al. 2020

View full text Add to dashboard Cite

The antidiabetic, hypoglycemic and oral glucose tolerance test (OGTT) activities of zinc oxide nanoparticles (ZnONPs) were assessed in mice. ZnONPs were prepared by reacting Zn(NO3)2.6H2O and NaOH solution at 70°C with continuous stirring and then characterized by transmission electron microscopy (TEM) and scanning electron microscopy (SEM) techniques. Diabetes was induced by the intraperitoneal injection of streptozotocin (STZ) in mice, and then the blood glucose levels were determined by the glucose oxidase method. The experimental results revealed that ZnONPs suggestively (p<0.001) declined the blood glucose levels (39.79%), while these reductions were 38.78% for the cotreatment of ZnONPs and insulin, and 48.60% for insulin, respectively. In the hypoglycemic study, ZnONPs (8 and 14 mg/kg b.w) reduced approximately 25.13 and 29.15% of blood glucose levels, respectively. A similar reduction was found in the OGTT test, which is also a dose- and time-dependent manner. Overall, ZnONPs possess a potential antidiabetic activity, which could be validated by further mechanistic studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Nanonutraceutics could be an important tool useful among the strategies adopted in managing health conditions, particularly tailored to patients who are not eligible for a conventional pharmacological therapy. Studies on follow up, use, and compliance of pharmaceuticals reported in the area [98][99][100][101], as well as communication strategies and assessment [102], should be extended also to nutraceuticals and carried out in view of exploiting the field to different health conditions, e.g., the ones clustered in the so-called "metabolic syndrome", which includes conditions ranging from obesity to dysmetabolism [103][104][105]. These latter are often related to the food intake/dietary habits of each person.…”

Section: From Nanopharmaceutics To Nanonutraceutics: a Bet For The Fumentioning

confidence: 99%

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

et al. 2020

Self Cite

View full text Add to dashboard Cite

Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations-nanopharmaceutics-have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing "Nanopharmaceutics: Part I-Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU" has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.Nanomaterials 2020, 10, 455 2 of 16 funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1). Nanomaterials 2020, 10, x FOR PEER REVIEW 2 of 17European Commission aims to lead innovation towards the development of these nanopharmaceutics by launching several funding opportunities within Member States, Associated Countries and Third Countries. The strategic plan for the next Horizon Europe framework programme has clearly set nanomedicines and advanced therapies as priorities. To succeed, the nanoproduct needs to be manufacturable at large scale and its quality assured in order to reach clinical trials. The topic is indeed of high scientific interest considering the number of scientific papers dealing with clinical trials and nanoparticles over the last twenty years (Figure 1).

show abstract

In vitro antidiabetic, antioxidant, antimicrobial, and cytotoxic activity of Murraya koenigii leaf extract intercedes ZnO nanoparticles

Sharma

Nagraik

Venkidasamy³

et al. 2022

Luminescence

View full text Add to dashboard Cite

Nanotechnology is an emerging field with tremendous potential and usage of medicinal plants and green preparation of nanoparticles (NPs) is one of the widely explored areas. These have been shown to be effective against different biological activities such as diabetes mellitus, cancer, antioxidant, antimicrobial, etc. The current studies focus on the green synthesis of zinc NPs (ZnO NPs) from aqueous leaf extract of Murraya koenigii (MK). The synthesized Murraya koeingii zinc oxide NPs (MK ZnO NPs) were characterized using UV-visible spectroscopy, dynamic light scattering (DLS), Fourier transform infrared (FTIR) spectroscopy, field emission scanning electron microscopy (FESEM), energy-dispersive spectrum (EDS) and cyclic voltammetry (CV). The synthesized MK ZnO NPs were evaluated for their in vitro antidiabetic, antioxidant, antimicrobial, and cytotoxic activity. They demonstrated significant antidiabetic and cytotoxic activity, as well as moderate free-radical scavenging and antibacterial activity.antibacterial and cytotoxic activity, antidiabetic activity, green synthesis, Murraya koenigii, zinc oxide nanoparticles | INTRODUCTIONM. koenigii (MK) also called curry leaf in the Indian family, is indigenous to Sri Lanka and other South Asian countries and belongs to the Rutaceae family, which includes over 150 genera and 1600 species. [1] MK plant is used for its antioxidative, antimicrobial, cytotoxic, antiulcer, positive inotropic, and cholesterol reducing activities. [2] Several compounds have been isolated from different parts. Mathur et al.(2011) confirmed the antifungal activity of some components of M. koenigii. [3] The apoptotic activity of maharini, pravadoline-D, and morpholine-I, carbazole alkaloids of M. koenigii showed effective results against the human myeloid cancer cell line HL-60. [4] Leaf extract was found positively to induce apoptosis in human myeloid cancer cell lines. [5] Mahanimbine, a phytocompound showed antidiabetic activity. By increasing the pancreatic secretion of insulin from beta-cells and by increasing the uptake of glucose, mahanimbine decreases blood sugar levels. Leaves have been shown to increase glycogenesis, while decreasing glycogenolysis and gluconeogenesis. [6] Diabetes mellitus (DM) is an endocrine metabolic disorder that shows elevated blood glucose levels due to an insufficient amounts of insulin [7,8] Currently, the overall global prevalence of diabetes for all age groups was estimated to be 2.0% (124 million people) in 1997, [9] 2.8% (171 million people) in 2000, 3.6% (221 million people) in 2010, and 4.4% (366 million people) in 2030 and will be 700.2 million people by 2045 (International Diabetes Federation, 2020). [9,10] Compared with developed countries, DM seems to be more prevalent in developing countries. As a result, diabetes has emerged as one of the most serious health threats, with a significant socioeconomic effect.The pharmacological interventions for the treatment of diabetes include the oral hypoglycaemic agents and insulin therapy. When

show abstract

Nanoparticle Delivery Systems in the Treatment of Diabetes Complications

Cited by 124 publications

References 206 publications

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

Biological efficacy of zinc oxide nanoparticles against diabetes: a preliminary study conducted in mice

Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods

In vitro antidiabetic, antioxidant, antimicrobial, and cytotoxic activity of Murraya koenigii leaf extract intercedes ZnO nanoparticles

Contact Info

Product

Resources

About